Literature DB >> 23184568

Considering an integrated nephrology care delivery model: six principles for quality.

L Lee Hamm1, Thomas H Hostetter, Rachel N Shaffer.   

Abstract

In 2012, 27 organizations will initiate participation in the Medicare Shared Savings Program as Accountable Care Organizations. This level of participation reflects the response of Centers for Medicare and Medicaid Services to criticism that the program as outlined in the proposed rule was overly burdensome, prescriptive, and too risky. Centers for Medicare and Medicaid Service made significant changes in the final rule, making the Accountable Care Organization program more attractive to these participants. However, none of these changes addressed the serious concerns raised by subspecialty societies-including the American Society of Nephrology-regarding care of patients with multiple chronic comorbidities and complex and end stage conditions. Virtually all of these concerns remain unaddressed, and consequently, Accountable Care Organizations will require guidance and partnership from the nephrology community to ensure that these patients are identified and receive the individualized care that they require. Although the final rule fell short of addressing the needs of patients with kidney disease, the Centers for Medicare and Medicaid Innovation presents an opportunity to test the potentially beneficial concepts of the Accountable Care Organization program within this patient population. The American Society of Nephrology Accountable Care Organization Task Force developed a set of principles that must be reflected in a possible pilot program or demonstration project of an integrated nephrology care delivery model. These principles include preserving a leadership role for nephrologists, encompassing care for patients with later-stage CKD and kidney transplants as well as ESRD, enabling the participation of a diversity of dialysis provider sizes and types, facilitating research, and establishing monitoring systems to identify and address preferential patient selection or changes in outcomes.

Entities:  

Mesh:

Year:  2012        PMID: 23184568      PMCID: PMC5024358          DOI: 10.2215/CJN.04460512

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN: 1555-9041            Impact factor:   8.237


  6 in total

Review 1.  Treatment of chronic kidney disease.

Authors:  Jeffrey M Turner; Carolyn Bauer; Matthew K Abramowitz; Michal L Melamed; Thomas H Hostetter
Journal:  Kidney Int       Date:  2011-12-14       Impact factor: 10.612

2.  Making good on ACOs' promise--the final rule for the Medicare shared savings program.

Authors:  Donald M Berwick
Journal:  N Engl J Med       Date:  2011-10-20       Impact factor: 91.245

3.  How the center for Medicare and Medicaid innovation should test accountable care organizations.

Authors:  Stephen M Shortell; Lawrence P Casalino; Elliott S Fisher
Journal:  Health Aff (Millwood)       Date:  2010-07       Impact factor: 6.301

4.  Accountable care organizations: accountable for what, to whom, and how.

Authors:  Elliott S Fisher; Stephen M Shortell
Journal:  JAMA       Date:  2010-10-20       Impact factor: 56.272

5.  The ACO regulations--some answers, more questions.

Authors:  John K Iglehart
Journal:  N Engl J Med       Date:  2011-04-13       Impact factor: 91.245

6.  Accountable care organizations and ESRD: the time has come.

Authors:  Allen R Nissenson; Franklin W Maddux; Ruben L Velez; Tracy J Mayne; Jess Parks
Journal:  Am J Kidney Dis       Date:  2012-03-28       Impact factor: 8.860

  6 in total
  2 in total

Review 1.  Socioeconomic disparities in chronic kidney disease.

Authors:  Susanne B Nicholas; Kamyar Kalantar-Zadeh; Keith C Norris
Journal:  Adv Chronic Kidney Dis       Date:  2015-01       Impact factor: 3.620

Review 2.  Value-based integrated (renal) care: setting a development agenda for research and implementation strategies.

Authors:  Pim P Valentijn; Claus Biermann; Marc A Bruijnzeels
Journal:  BMC Health Serv Res       Date:  2016-08-02       Impact factor: 2.655

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.